Fate Therapeutics (FATE) vs Invivyd (IVVD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Fate Therapeutics (FATE) has outperformed Invivyd (IVVD) over the past year, gaining 54.7% versus a loss of 55.3%. Over five years, FATE leads with a -96.5% price change compared with -97.8% for IVVD. Fate Therapeutics is the larger company by market cap ($247.4 million vs $204.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FATE | IVVD |
|---|---|---|
| Share price | $2.07 | $0.6942 |
| Market cap | $247.43M | $204.62M |
| 1-day change | -3.95% | -4.72% |
| YTD return | +119.39% | -70.50% |
| 1-year return | +54.68% | -55.30% |
| 5-year return | -96.49% | -97.75% |
| EPS (TTM) | $-1.05 | $-0.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.23 | $3.07 |
| 52-week low | $0.95 | $0.528 |
| Distance from 52-week high | -36.07% | -77.39% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +177.97% | +1340.51% |
| Average volume | 1.89M | 4.78M |
| Shares outstanding | 119.82M | 294.76M |
| Employees | 161 | 122 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FATE has outperformed IVVD by 110.0 percentage points over the past year.
About Fate Therapeutics
FATE stock →Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 122 employees
FATE vs IVVD FAQ
Which is bigger, Fate Therapeutics or Invivyd?
Fate Therapeutics (FATE) is larger, with a market capitalization of $247.43M compared with $204.62M for Invivyd (IVVD).
Which stock has performed better over the past year, FATE or IVVD?
FATE returned +54.68% over the past 12 months, compared with -55.30% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are Fate Therapeutics and Invivyd in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.